Skip to main content

Q32 Bio Inc.

QTTB
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0001661998

In the last 90 days, Q32 Bio Inc. insiders filed 0 open-market purchases and 3 sales; 72 institutions reported holding it in 13F filings for Q2 2026, worth $282.8M in total; no superinvestor holds it.

Open-market trades, last 90 days

Open-market purchases (P) and sales (S) by Q32 Bio Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.

Open-market buys
0 filings
Open-market sells
3 filings
3 insiders, $275.1K in total
Insiders trading
3
Net value
−$275.1K
Purchases minus sales

Insider roster

Directors, officers and 10% owners who have filed a Form 4 for Q32 Bio Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.

Insider roster for Q32 Bio Inc.
NameTitleLast reported holdingLast filingFilings, past year
Morrison Jodie PopeCEO343,259Aug 27, 20265
Kalowski LeeCFO and President138,471Aug 27, 20265
Violette Shelia M.Chief Scientific Officer127,771Aug 27, 20264
Tzianabos ArthurDirector7,983Jul 21, 20262
Lundberg Sven AnteDirector–Jul 21, 20263
Laporte KathleenDirector–Jul 21, 20263
Iwicki Mark TDirector–Jul 21, 20262
Xu DiyongDirector, 10% Owner625,000IndirectJul 21, 20263
Manke IsaacDirector53,521Jul 21, 20263
Grayzel David S.Director–Jul 21, 20263
Thistle MaryDirector–Jul 21, 20262
OrbiMed Advisors LLCDirector, 10% Owner625,000IndirectJun 1, 20261
OrbiMed Capital GP VII LLCDirector, 10% Owner625,000IndirectJun 1, 20261
OrbiMed Genesis GP LLCDirector, 10% Owner625,000IndirectJun 1, 20261
Campagna JasonChief Medical Officer37,500Feb 26, 20250
Alloway PaulSee Remarks2,596Apr 23, 20240
Michaud Charles JrSee Remarks927Apr 23, 20240
Seymour AlbertSee Remarks150,874Sep 8, 20230
Jordan JulieChief Medical Officer7,496Aug 7, 20230
Gillis StevenDirector–Jun 15, 20230
Patterson Matthew RDirector–Jun 15, 20230
Reicin AliseDirector–Jun 15, 20230
Poulton Jeffrey V.Director–Jun 15, 20230
Smith W BradfordSee remarks14,219Feb 27, 20230
Blum Michael LeeChief Commercial Officer13,538Feb 27, 20230
Gregory Richard J.Director–Jun 17, 20220
Parmar KushDirector–Jun 17, 20220
Kelly Timothy PChief Operating Officer2,224Feb 28, 20220
Cohn GabrielChief Medical Officer2,629Jan 12, 20220

Insider trades

Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.

Insider trades
Filed (ET)Trade dateFiling delayInsiderTransactionSharesAvg priceValueHolding changeFlags
Aug 27, 2026 (view filing)4:10 PM ETAug 252 daysMorrison Jodie PopeCEOSSale−9.85K$16.56−$163.0K−2.8%343.3K after
Aug 27, 2026 (view filing)4:10 PM ETAug 252 daysKalowski LeeCFO and PresidentSSale−3.97K$16.56−$65.8K−2.8%138.5K after
Aug 27, 2026 (view filing)4:10 PM ETAug 252 daysViolette Shelia M.Chief Scientific OfficerSSale−2.80K$16.56−$46.3K−2.1%127.8K after
Jun 1, 2026 (view filing)9:13 PM ETMay 284 daysOrbiMed Advisors LLC and 2 othersDirector, 10% OwnerPPurchase+1.88M$8.00+$15.0MNew position625.0K after2 lotsDuplicate filing
Jun 1, 2026 (view filing)May 284 daysXu DiyongDirector, 10% OwnerPPurchase+1.88M$8.00+$15.0MNew position625.0K after2 lots
Feb 27, 2026 (view filing)Feb 252 daysKalowski LeeCFO and PresidentSSale−4.00K$4.51−$18.0K−10.0%35.9K after
Feb 27, 2026 (view filing)Feb 252 daysMorrison Jodie PopeCEOSSale−9.90K$4.51−$44.6K−10.0%89.1K after
Feb 27, 2026 (view filing)Feb 252 daysViolette Shelia M.Chief Scientific OfficerSSale−2.81K$4.51−$12.7K−4.8%55.6K after
Dec 4, 2025 (view filing)Dec 22 daysMorrison Jodie PopeCEOSSale−22.5K$3.46−$77.9K−18.5%99.0K after
Dec 4, 2025 (view filing)Dec 22 daysKalowski LeeCFO and PresidentSSale−9.07K$3.46−$31.4K−18.5%39.9K after
Aug 28, 2025 (view filing)Aug 262 daysMorrison Jodie PopeCEOSSale−10.5K$1.80−$18.9K−8.0%121.5K after
Aug 28, 2025 (view filing)Aug 262 daysViolette Shelia M.Chief Scientific OfficerSSale−2.99K$1.80−$5.38K−4.9%58.4K after
Aug 28, 2025 (view filing)Aug 262 daysKalowski LeeCFO and PresidentSSale−4.24K$1.80−$7.63K−8.0%49.0K after
Aug 14, 2024 (view filing)Mar 25142 daysLateTzianabos ArthurDirectorSSale−265$24.20−$6.41K−3.2%7.98K after
Apr 23, 2024 (view filing)Mar 2529 daysLateAlloway PaulSee RemarksSSale−268$24.21−$6.49K−9.4%2.60K after
Apr 23, 2024 (view filing)Mar 2529 daysLateMichaud Charles JrSee RemarksSSale−75$24.20−$1.81K−7.5%927 after
Feb 15, 2024 (view filing)Jan 937 daysLateTzianabos ArthurDirectorSSale−13.0K$0.57−$7.43K−9.2%128.8K after10b5-1
Jan 5, 2024 (view filing)Jan 32 daysAlloway PaulSee RemarksSSale−7.28K$0.57−$4.15K−20.6%28.0K after
Jan 5, 2024 (view filing)Jan 32 daysMichaud Charles JrSee RemarksSSale−1.71K$0.57−$973.56−12.8%11.6K after
Sep 8, 2023 (view filing)Sep 62 daysSeymour AlbertSee RemarksSSale−1.45K$1.15−$1.67K−1.0%150.9K after10b5-1
Aug 7, 2023 (view filing)Aug 34 daysJordan JulieChief Medical OfficerSSale−1.85K$1.39−$2.58K−19.8%7.50K after3 lots10b5-1
Aug 4, 2023 (view filing)Aug 22 daysJordan JulieChief Medical OfficerSSale−99$1.31−$129.69−3.5%2.77K after10b5-1
Mar 6, 2023 (view filing)Mar 24 daysAlloway PaulSee RemarksSSale−11.0K$1.45−$15.9K−39.6%16.7K after
Jan 11, 2023 (view filing)Jan 92 daysBlum Michael LeeChief Commercial OfficerSSale−2.45K$1.39−$3.41K−15.3%13.5K afterAmended
Jan 11, 2023 (view filing)Jan 92 daysAlloway PaulSee RemarksSSale−3.09K$1.39−$4.30K−13.3%20.1K afterAmended
Jan 11, 2023 (view filing)Jan 92 daysSeymour AlbertSee RemarksSSale−3.62K$1.39−$5.03K−2.5%143.2K afterAmended
Jan 11, 2023 (view filing)Jan 92 daysSmith W BradfordSee RemarksSSale−3.73K$1.39−$5.18K−20.8%14.2K after
Jan 11, 2023 (view filing)Jan 92 daysTzianabos ArthurDirectorSSale−10.6K$1.39−$14.8K−8.9%108.4K after
Jan 12, 2022 (view filing)Jan 57 daysLateSmith W BradfordCFO & TreasurerSSale−2.18K$3.78−$8.25K−33.1%4.42K after
Jan 12, 2022 (view filing)Jan 57 daysLateKelly Timothy PChief Operating OfficerSSale−1.41K$3.78−$5.31K−38.7%2.22K after
Jan 12, 2022 (view filing)Jan 57 daysLateSeymour AlbertChief Scientific OfficerSSale−1.66K$3.78−$6.28K−1.2%131.6K after
Jan 12, 2022 (view filing)Jan 57 daysLateCohn GabrielChief Medical OfficerSSale−1.66K$3.78−$6.28K−38.7%2.63K after
Jan 12, 2022 (view filing)Jan 57 daysLateTzianabos ArthurPresident & CEOSSale−5.35K$3.78−$20.2K−5.9%86.0K after
Sep 8, 2021 (view filing)Sep 35 daysKelly Timothy PSee Remarks.SSale−54$7.70−$415.8−100.0%0 after
Sep 8, 2021 (view filing)Mar 1191 daysKelly Timothy PSee RemarksSSale−6.23K$11.16−$69.5K−100.0%0 afterAmended